Name (Synonyms) | Correlation | |
---|---|---|
drug2819 | favipiravir Wiki | 1.00 |
drug2331 | Standard of care therapy Wiki | 1.00 |
drug1822 | Placebo Wiki | 0.06 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The purpose of this clinical trial is to determine the efficacy of Previfenon® (EGCG) to prevent COVID-19, enhance systemic immunity, and decrease the frequency and intensity of selected symptoms when used as pre-exposure chemoprophylaxis to SARS-CoV-2.
Description: A positive case or event of COVID-19 is defined as a patient with acute respiratory illness presenting fever (37.8º C); at least one of the following symptoms: odynophagia, cough, myalgia, or dyspnea; and a specific positive rtPCR test for SARS-CoV-2.
Measure: Event of clinical acute respiratory disease with a diagnosis of COVID-19 confirmed with rtPCR Time: The date for censoring a case will be defined as that date when the rtPCR test results positive minus 4 days, with the aim to calculate the time free of clinically defined COVID-19 infection over 40 to 70 days of interventionDescription: Rate of positive cases for IgM and IgG anti-SARS-CoV-2 measured by immunochromatographic test in treatment and placebo group at the end of the study
Measure: Rate of positive cases for IgM and IgG anti-SARS-CoV-2 Time: Positive cases in each two-week examination and to the end of the study over 40 to 70 days of interventionDescription: Rate of asymptomatic cases defined as a positive rtPCR for SARS-CoV-2 viral RNA but with no symptoms of COVID-19 in treatment and placebo group at the end of the study, and a composite outcome considering symptomatic and asymptomatic cases (i.e. all cases with positive rtPCR test)
Measure: Composite outcome considering symptomatic and asymptomatic cases with positive rtPCR test Time: Positive cases in each two-weeks examination and to the end of the study over 40 to 70 days of interventionDescription: Rate of hospitalizations due to any acute respiratory infection at the end of the study
Measure: Hospitalization due to any acute respiratory infection Time: Positive cases in each two-week examination visit and to the end of the study over 40 to 70 days of interventionDescription: Global frequency of events of upper and lower airway respiratory infections
Measure: Event of upper and lower airway respiratory infection Time: Positive cases in each two-week examination and to the end of the study over 40 to 70 days of interventionDescription: Registry of Visual Analogue Scale (VAS) in the log diary of every healthcare worker for the following selected symptoms: cough, muscle pain (myalgia); difficulty breathing (dyspnea); loss of smell (anosmia); loss of taste (ageusia); pain when swallowing (odynophagia, sore throat); and finally headache
Measure: Exploratory outcome: Frequency and intensity of selected symptoms for COVID-19 Time: Different VAS scores calculated each two-week examination visit over 40 to 70 days of interventionDescription: Elevation of liver enzymes over 5 times the normal value
Measure: Primary safety outcome: event of major hepatic harm Time: Cases accounted by liver profile lab test in each two-week examination visit over 40 to 70 days of intervention.Description: Elevation of liver enzymes over 5 times the normal value
Measure: Event of liver enzymes over 3 times the normal value Time: Cases accounted by liver profile lab test in each two-week examination visit over 40 to 70 days of interventionDescription: Any adverse event reported over the intervention period
Measure: Frequency of adverse events Time: Records of self-reported adverse effects on log dairy accounted in each examination visit over 40 to 70 days of intervention